X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

HCM

Closed

Hutchmed Drc

15.41
+0.36 (+2.39%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 15.05
Day's Range: 15.26 - 15.53
Send
When Written:
 
12.485
HUTCHMED, also known as Hutchison China MediTech, is a biopharmaceutical company that focuses on discovering, developing, and commercializing targeted therapies for the treatment of cancer and other diseases. The company has a presence in China, the United States, and Europe.

DRC, or Deciphera Resources Corporation, is a subsidiary of HUTCHMED that is focused on the development of kinase inhibitors for the treatment of cancer and other diseases. DRC's lead product candidate is a kinase inhibitor called ripretinib, which is being developed for the treatment of gastrointestinal stromal tumors (GIST) and other solid tumors.

HUTCHMED has a strong pipeline of drug candidates in various stages of development, including several kinase inhibitors and immune-oncology therapies. The company has partnerships and collaborations with major pharmaceutical companies, academic institutions, and research organizations to advance its drug development programs.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.11
X